5-alpha Reductase inhibitors and risk of male breast cancer: a systematic review and meta-analysis
Int. braz. j. urol
;
44(5): 865-873, Sept.-Oct. 2018. tab, graf
Article
in English
| LILACS
| ID: biblio-975633
ABSTRACT
Abstract Objective:
To assess the relationship between 5α-reductase inhibitors (5ARIs) and the risk of male breast cancer (MBC). Material andMethods:
We systematically searched Medline via PubMed, Embase and the Cochrane Library Central Register up to May 2017 to identify published articles related to 5ARIs and the risk of MBC.Results:
Summary effect estimates were calculated by a random-effect model, and tests for multivariable-unadjusted pooled risk ratios (RR) and heterogeneity, as well as the sensitivity analyses were conducted to assess publication bias. All four studies were conducted in a quality assessment according to the Newcastle Ottawa Scale system. The strength of association between 5ARIs and the prevalence of MBC was evaluated by using summarized unadjusted pooled RR with a 95% confidence interval [CI]. Four studies involving 595.776 participants, mean age range from 60 to 73.2 years old, were included in a meta-analysis, which produced a summary unadjusted RR of the risk of MBC for the treatment of 5ARIs of 1.16 (95% CI 0.85-1.58, P=0.36) and the multivariable-adjusted RR is 1.03, (95% CI 0.75-1.41, p=0.86). There was no heterogeneity among included studies (I2=0%, P=0.49). Estimates of total effects were generally consistent with the sensitivity.Conclusion:
We did not observe a positive association between the use of 5ARIs and MBC. The small number of breast cancer cases exposed to 5ARIs and the lack of an association in our study suggest that the development of breast cancer should not influence the prescribing of 5ARIs therapy.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Breast Neoplasms, Male
/
5-alpha Reductase Inhibitors
Type of study:
Etiology study
/
Risk factors
/
Systematic reviews
Limits:
Aged
/
Humans
/
Male
Language:
English
Journal:
Int. braz. j. urol
Journal subject:
Urology
Year:
2018
Type:
Article
Affiliation country:
China
Institution/Affiliation country:
GuangZhou Medical University/CN
Similar
MEDLINE
...
LILACS
LIS